logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Hong Kong Stock Movement | China Resources Building Materials Technology (01313.HK) Falls Over 2%; Loss Attributable to Owners for First Three Quarters Approximately RMB 796 Million, Turning from Profit to Loss Year-on-Year

date
27/10/2026
Zhitong Finance APP has learned that China Resources Building Materials Technology (01313.HK) fell more than 2%, down 2.05% as of press time, at HK$0.955, with a turnover of HK$3.3486 million.
Latest
3 m ago
Getein Biotech (603387.SH) released its performance for the first three quarters, with net profit attributable to shareholders of RMB 232 million, up 44.76% year on year.
5 m ago
Jilin Expressway (601518.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 370 million yuan, a year-on-year decrease of 6.49%.
8 m ago
The Philippine peso fell to a record low of 64.033 against the US dollar.
8 m ago
Hong Kong Stock Movement | Duiba (01753.HK) Rises Over 7% in Late Trading; AI Short Drama Business Scales Rapidly, Management Expects Three Consecutive Months of Net Profit
8 m ago
GSK expects the number of cancer drugs in its clinical trials to nearly double next year.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.